Previous 10 | Next 10 |
2023-03-07 00:26:15 ET The US FDA has told BioMarin Pharmaceutical ( NASDAQ: BMRN ) that it is extending the action date on the company's Biologics License Application for Roctavian (valoctocogene roxaparvovec) to June 30. The FDA said that a three-year data analysis provi...
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif. , March 6, 2023 /PRNewswire/...
2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...
BioMarin to Participate in Three Investor Conferences in March PR Newswire Cowen Healthcare Conference on March 8 in Boston Barclays Global Healthcare Conference on March 15 in Miami Jefferies Biotech on the Bay Summit on March 16 in Miami...
BioMarin Pharmaceutical Inc. (BMRN) Q4 2022 Results Conference Call February 28, 2023 04:30 PM ET Company Participants Traci McCarty - Group VP, IR JJ Bienaimé - Chairman and CEO Jeff Ajer - EVP and Chief Commercial Officer Hank Fuchs - President, Worldwide R&...
BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q4 GAAP EPS of $0.00 beats by $0.07 . Revenue of $537.5M (+19.5% Y/Y) misses by $0.74M . Non-GAAP Income increased to $67.4 million for the fourth quarter of 2022 compared to Non-GAAP Income of $7.1 million for th...
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business PR Newswire VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 Billion ...
BioMarin Pharmaceutical ( NASDAQ: BMRN ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is $0.39 and the consensus Revenue Estimate is $538.24M (+19.7% Y/Y). Over the last 3 months, EPS estimates have seen ...
BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023 PR Newswire SAN RAFAEL, Calif. , Feb. 14, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairm...
Investors can win big when they invest in healthcare stocks that are likely takeover targets. These companies often may not be that profitable, but because of the potential for their products or for their growing revenue, larger companies are willing to pay a premium for them. That often mean...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...